FHTX
Foghorn Therapeutics Inc.NASDAQHealthcare$4.93+0.61%ClosedMarket Cap: $289.4M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-2.83
P/S
9.27
EV/EBITDA
-3.39
DCF Value
$-12.32
FCF Yield
-30.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
29.8%
Operating Margin
-265.6%
Net Margin
-240.3%
ROE
88.3%
ROA
-37.5%
ROIC
-58.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $9.2M | 91.3% | $-19.6M | $-21.7M | $-0.35 | — |
| FY 2025 | $30.9M | 89.2% | $-82.1M | $-74.3M | $-1.18 | — |
| Q3 2025 | $8.2M | -145.3% | $-18.5M | $-15.8M | $-0.25 | — |
| Q2 2025 | $7.6M | 88.1% | $-21.1M | $-17.9M | $-0.28 | — |
| Q1 2025 | $6.0M | 100.0% | $-22.9M | $-18.8M | $-0.30 | — |
| Q4 2024 | $2.9M | 100.0% | $-24.0M | $-19.5M | $-0.31 | — |
| FY 2024 | $22.6M | 100.0% | $-102.7M | $-86.6M | $-1.58 | — |
| Q3 2024 | $7.8M | 100.0% | $-23.9M | $-19.1M | $-0.31 | — |
| Q2 2024 | $6.9M | 100.0% | $-26.6M | $-23.0M | $-0.45 | — |
| Q1 2024 | $5.0M | 100.0% | $-28.2M | $-25.0M | $-0.59 | — |
| Q4 2023 | $5.8M | 85.2% | $-25.5M | $-24.1M | $-0.57 | — |
| FY 2023 | $34.2M | 100.0% | $-107.9M | $-98.4M | $-2.34 | — |